WO1995030420A1 - Use of vitamin e tocopheryl derivatives in ophthalmic compositions - Google Patents

Use of vitamin e tocopheryl derivatives in ophthalmic compositions Download PDF

Info

Publication number
WO1995030420A1
WO1995030420A1 PCT/US1995/005730 US9505730W WO9530420A1 WO 1995030420 A1 WO1995030420 A1 WO 1995030420A1 US 9505730 W US9505730 W US 9505730W WO 9530420 A1 WO9530420 A1 WO 9530420A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
composition
ophthalmic
tocopheryl
ester
Prior art date
Application number
PCT/US1995/005730
Other languages
French (fr)
Inventor
Manoj L. Maniar
Original Assignee
Alcon Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories, Inc. filed Critical Alcon Laboratories, Inc.
Priority to EP95919064A priority Critical patent/EP0708646A1/en
Priority to AU24762/95A priority patent/AU684950B2/en
Publication of WO1995030420A1 publication Critical patent/WO1995030420A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Definitions

  • the present invention relates generally to ophthalmic compositions.
  • the present invention relates to the use of certain vitamin E tocopheryl derivatives to provide comfortable, non-irritating ophthalmic compositions.
  • the present invention relates to the use of these vitamin E tocopheryl derivatives to increase the solubility of poorly soluble ophthalmic agents in aqueous compositions.
  • the vitamin E tocopheryl derivatives useful in the present invention shall be referred to as "vitamin E tocopheryl derivatives" or “vitamin E derivatives” or "TPGS.”
  • Stinging and burning sensations, as well as general discomfort, are often associated with the topical ophthalmic application of certain types of ophthalmic agents. It is believed that such ocular discomfort is due to the presence of certain functional groups in these agents.
  • agents which produce ocular discomfort include, but are not limited to: -blockers such as betaxolol; prostaglandins and prostaglandin derivatives; muscarinics such as pilocarpine; ⁇ - adrenergics such as epinephrine, clonidine and apraclonidine; cholinergics such as carbachol; and non-steroidal anti-inflammatory drugs ("NSAIDs”) such as diclofenac and suprofen.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • US 4,960,799 discloses storage stable aqueous ophthalmic compositions containing diclofenac and/or its pharmaceutically acceptable salts.
  • the Nagy compositions include EDTA and a solubilizer such as ethoxylated castor oil.
  • vitamin E tocopheryl derivatives renders such compositions very comfortable and non-irritating. It has also been discovered that these vitamin E derivatives greatly enhance the aqueous solubility of many compounds which are only sparingly soluble in aqueous compositions.
  • Vitamin E tocopheryl derivatives are water-soluble, biologically-active vitamin E analogues. These vitamin E derivatives have been used as alternatives to vitamin E, especially where water-solubility is desired.
  • US Patent No.3, 102,078 describes the use of these derivatives to solubilize naturally-occurring water-insoluble vitamins, such as vitamins A, D and E. The use of these vitamin E derivatives to enhance the absorption of vitamin A and cyclosporin have also been reported. See, for example, Sokol, R.J. et al., "Improvement of Cyclosporin Absorption in Children after Liver Transplantation by Means of Water-soluble Vitamin E," The Lancet. 338:212-215 (1991), and Argao, E.A. et al., "d- - Tocopheryl Polyethylene Glycol-1000 Succinate Enhances the Absorption of
  • the vitamin E tocopheryl derivatives useful in the compositions of the present invention are highly water-soluble polyoxyalkylene glycol esters of vitamin E tocopheryl esters of a dicarboxylic acid.
  • Representative esters of this type include the polyoxyethylene glycol esters of vitamin E tocopheryl esters of a dicarboxylic acid wherein the polyoxyethylene glycol moiety of the ester (sometimes merely referred to as the polyoxyethylene glycol moiety of the ester) has a molecular weight in the range from about 600 to about 6000, preferably in the range from about 600 to about 1500.
  • Such esters and methods for their preparation are disclosed in US Patent No. 2,680,749 (Cawley et al.).
  • the most preferred ester is the ⁇ -tocopheryl polyoxyethylene glycol (1000) succinate, a polyoxyethylene glycol ester of ⁇ -tocopheryl succinate wherein the polyoxyethylene glycol moiety of the molecule has an average molecular weight of about 1000.
  • one or more vitamin E derivatives are used in the compositions of the present invention in an amount less than about 30 percent by weight (wt%). If the vitamin E derivatives are used as solubilizing agents, it is preferred to use an amount between about 0.1 and about 20 wt%, most preferably between about 0.1 and about 5 wt%. When the vitamin E derivatives are used to enhance comfort, it is preferred to use an amount between about 0.1 and about 20 wt%, most preferably between about 0.5 and about 10 wt%.
  • Suitable ophthalmic agents which may be included in the compositions of the present invention and administered via the method of the present invention include, but are not limited to, the racemic and enantiomeric forms and ophthalmically acceptable salts and esters of following types of compounds:
  • - glaucoma agents such as: -blockers (e.g., betaxolol, timolol, and carteolol); ⁇ -agonists (e.g., apraclonidine and related 2-substituted amino imidazolines); carbonic anhydrase inhibitors; dopamine agonists and antagonists; miotic cholinergics (e.g., pilocarpine and carbachol); prostaglandins and prostaglandin derivatives; ACE inhibitors; steroids (e.g., glucocorticoids and angiostatic steroids); and calcium channel blockers; anti-hypertensives; - non-steroidal anti-inflammatory agents, including but not limited to those classified as aryl- or heteroaryl- alkanoic acids such as diclofenac, flurbiprofen, suprofen, ketorolac, indomethacin and ketoprofen; steroidal anti-inflammatory agents, such as fluorometholone
  • cephalosporins such as cefamandole
  • anti-fungals such as natamycin
  • anti-virals such as acyclovir and ganciclovir
  • - anti-cataract agents and anti-oxidants anti-allergies
  • anti-metabolites such as 5-fluorouracil (5-FU) and methotrexate
  • immunosuppressants such as cyclosporin, FK-506 and leflunimide
  • growth factors such as EGF, FGF, PDGF
  • Combinations of ophthalmic agents may also be used in the compositions of the present invention. Further, in formulations without ophthalmic agents, the present invention may also serve to supplement tears in the prevention or treatment of dry eye.
  • compositions of the present invention may additionally include other ophthalmically acceptable components: for example, buffers (e.g., phosphate, borate and citrate), chelating agents (e.g., EDTA), preservatives, (e.g., benzalkonium chloride, Polyquad ® and Dymed ® ) and tonicity agents (e.g., sodium chloride and mannitol).
  • buffers e.g., phosphate, borate and citrate
  • chelating agents e.g., EDTA
  • preservatives e.g., benzalkonium chloride, Polyquad ® and Dymed ®
  • tonicity agents e.g., sodium chloride and mannitol
  • compositions of the present invention may also include viscosity modifying agents such as: cellulosic ethers, such as, hydroxypropyl methyl cellulose (HPMC), hydroxyethyl cellulose (HEC), ethyl hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, and carboxymethyl cellulose; carbomers (Carbopol ); polyvinyl alcohol; polyvinyl pyrrolidone; alginates; carrageenans; and guar, karaya, agarose, locust bean, tragacanth and xanthan gums.
  • concentration of such viscosity modifiers will vary between about 0.1 to about 5 wt%, but such formulations will generally have a viscosity between about 10 and about 1000 centipoise.
  • the ophthalmic compositions containing TPGS may additionally contain polymers which will undergo sol-to-gel transition upon exposure to physical or chemical stimuli, such as changes in pH, ion concentration, and/or temperature.
  • the ophthalmic agents contained in the compositions of the present invention may optionally be encapsulated in microparticles. These loaded microparticles can be dispersed in aqueous vehicles containing TPGS to improve comfort.
  • water-soluble or water-insoluble complexes of the ophthalmic agent can be incorporated in a vehicle containing TPGS.
  • Example of water-soluble complexes include traditional complexes formed between the ophthalmic agent and caffeine, cyclodextrins, salicylates, benzoates.
  • Examples of water insoluble complexes include ophthalmic agent - drug resin complexes.
  • Vitamin E TPGS (1000) 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0
  • Formulation D was prepared as follows, and Formulations A-C and E-G were prepared similarly.
  • a 10% (w/v) stock solution of vitamin E TPGS was prepared as follows.
  • Approximately 150 g of vitamin E TPGS was melted in a beaker by heating on a hot plate with stirring to ensure homogeneity. About 100 grams (g) of the molten TPGS was then added into 800 milliliters (mL) of near-boiling double distilled water. This mixture was stirred and allowed to cool to room temperature to ensure complete dissolution. Sufficient water was then added to the above solution to make a liter of stock solution.
  • Sodium diclofenac (0.3 g) was added to 90 mL of 10% TPGS stock solution. After complete dissolution of the diclofenac, the each of following ingredients were sequentially added to the solution with stirring so that each ingredient was completely dissolved before the next ingredient was added: 1.5 g of arginine, 9.0 g of mannitol, 4.5 g of boric acid, 3.6 g of tromethamine and 0.3 g of edetate sodium. To the above solution was added 6.0 mL of 0.5% solution of benzalkonium chloride, followed by the addition of 15 mL of 2% solution of HPMC. An additional 150 mL of water were added and the pH of the formulation adjusted to 7.4 with HCI and/or NaOH. To the resulting solution, enough water was added to bring the total solution volume to 300 mL. The osmolality of the final solution was about 300mOsm/kg.
  • composition is another representative composition of the present invention, wherein a prostaglandin complexed with cyclodextrin is formulated in accordance with the teachings of the present invention.
  • the following formulation is another representative composition of the present invention, wherein a prostaglandin bound to Duolite® (cholestyramine resins, available from Rohm & Haas, Philadelphia, Pennsylvania) is formulated in accordance with the teachings of the present invention.
  • Duolite® cholestyramine resins, available from Rohm & Haas, Philadelphia, Pennsylvania
  • a prostaglandin (0.75 g) is dissolved in 200 mL of water. Finely divided Duolite (0.75 g) is added, and the solution allowed to equilibrate for 2 hours, during which time about 95% of the drug becomes bound to the resin.
  • appropriate amounts of tromethamine, boric acid, BAC, edetate sodium and mannitol are added to 90 mL of the 10% TPGS stock solution. The two parts are then mixed and the pH adjusted to 7.4 with HCI and/or NaOH. Enough water is then added to the formulation to bring the final volume to 300 mL.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed are ophthalmic compositions containing vitamin E tocopheryl derivatives which are comfortable and non-irritating. In addition, these vitamin E tocopheryl derivatives significantly increase the aqueous solubility of certain poorly soluble ophthalmic agents.

Description

USE OF VITAMIN E TOCOPHERYL DERIVATIVES IN OPHTHALMIC COMPOSITIONS
Background of the Invention
The present invention relates generally to ophthalmic compositions. In particular, the present invention relates to the use of certain vitamin E tocopheryl derivatives to provide comfortable, non-irritating ophthalmic compositions. In addition, the present invention relates to the use of these vitamin E tocopheryl derivatives to increase the solubility of poorly soluble ophthalmic agents in aqueous compositions. For purposes of the present specification, the vitamin E tocopheryl derivatives useful in the present invention shall be referred to as "vitamin E tocopheryl derivatives" or "vitamin E derivatives" or "TPGS."
Stinging and burning sensations, as well as general discomfort, are often associated with the topical ophthalmic application of certain types of ophthalmic agents. It is believed that such ocular discomfort is due to the presence of certain functional groups in these agents. Examples of such agents which produce ocular discomfort include, but are not limited to: -blockers such as betaxolol; prostaglandins and prostaglandin derivatives; muscarinics such as pilocarpine; α- adrenergics such as epinephrine, clonidine and apraclonidine; cholinergics such as carbachol; and non-steroidal anti-inflammatory drugs ("NSAIDs") such as diclofenac and suprofen.
There have been a number of attempts to formulate topical ophthalmic compositions to reduce the inherent discomfort associated with these ophthalmic agents. Such attempts include those described in US 4,559,343 (Han et al.), US 4,911 ,920 (Jani et al.), US 5,093,126 (Jani et al.), and US 5,212,162 (Missel et al.). Han et al. describe the addition of xanthine derivatives, such as caffeine, to decrease the stinging associated with topical ocular application of NSAIDs. The two Jani et al. references teach the addition of certain ion-exchange resins to compositions of -blockers to increase comfort and to provide sustained release. Missel et al. teach combinations of gelling polysaccharides and finely-divided drug carrier substrates ("DCS") which provide comfortable and sustained release ophthalmic compositions.
In addition, US 4,960,799 (Nagy), discloses storage stable aqueous ophthalmic compositions containing diclofenac and/or its pharmaceutically acceptable salts. The Nagy compositions include EDTA and a solubilizer such as ethoxylated castor oil.
Summary of the Invention
It has now been unexpectedly discovered that the addition of certain vitamin E tocopheryl derivatives to ophthalmic compositions renders such compositions very comfortable and non-irritating. It has also been discovered that these vitamin E derivatives greatly enhance the aqueous solubility of many compounds which are only sparingly soluble in aqueous compositions.
Detailed Description of the Invention
Vitamin E tocopheryl derivatives are water-soluble, biologically-active vitamin E analogues. These vitamin E derivatives have been used as alternatives to vitamin E, especially where water-solubility is desired. In addition, US Patent No.3, 102,078 describes the use of these derivatives to solubilize naturally-occurring water-insoluble vitamins, such as vitamins A, D and E. The use of these vitamin E derivatives to enhance the absorption of vitamin A and cyclosporin have also been reported. See, for example, Sokol, R.J. et al., "Improvement of Cyclosporin Absorption in Children after Liver Transplantation by Means of Water-soluble Vitamin E," The Lancet. 338:212-215 (1991), and Argao, E.A. et al., "d- - Tocopheryl Polyethylene Glycol-1000 Succinate Enhances the Absorption of
Vitamin D in Chronic Cholestatic Liver Disease of Infancy and Childhood," Pediatric Res.. 31 (2):146-150 (1992).
The vitamin E tocopheryl derivatives useful in the compositions of the present invention are highly water-soluble polyoxyalkylene glycol esters of vitamin E tocopheryl esters of a dicarboxylic acid. Representative esters of this type include the polyoxyethylene glycol esters of vitamin E tocopheryl esters of a dicarboxylic acid wherein the polyoxyethylene glycol moiety of the ester (sometimes merely referred to as the polyoxyethylene glycol moiety of the ester) has a molecular weight in the range from about 600 to about 6000, preferably in the range from about 600 to about 1500. Such esters and methods for their preparation are disclosed in US Patent No. 2,680,749 (Cawley et al.). The most preferred ester is the α-tocopheryl polyoxyethylene glycol (1000) succinate, a polyoxyethylene glycol ester of α-tocopheryl succinate wherein the polyoxyethylene glycol moiety of the molecule has an average molecular weight of about 1000.
In general, one or more vitamin E derivatives are used in the compositions of the present invention in an amount less than about 30 percent by weight (wt%). If the vitamin E derivatives are used as solubilizing agents, it is preferred to use an amount between about 0.1 and about 20 wt%, most preferably between about 0.1 and about 5 wt%. When the vitamin E derivatives are used to enhance comfort, it is preferred to use an amount between about 0.1 and about 20 wt%, most preferably between about 0.5 and about 10 wt%.
Suitable ophthalmic agents which may be included in the compositions of the present invention and administered via the method of the present invention include, but are not limited to, the racemic and enantiomeric forms and ophthalmically acceptable salts and esters of following types of compounds:
- glaucoma agents, such as: -blockers (e.g., betaxolol, timolol, and carteolol); α-agonists (e.g., apraclonidine and related 2-substituted amino imidazolines); carbonic anhydrase inhibitors; dopamine agonists and antagonists; miotic cholinergics (e.g., pilocarpine and carbachol); prostaglandins and prostaglandin derivatives; ACE inhibitors; steroids (e.g., glucocorticoids and angiostatic steroids); and calcium channel blockers; anti-hypertensives; - non-steroidal anti-inflammatory agents, including but not limited to those classified as aryl- or heteroaryl- alkanoic acids such as diclofenac, flurbiprofen, suprofen, ketorolac, indomethacin and ketoprofen; steroidal anti-inflammatory agents, such as fluorometholone, dexamethasone, prednisolone, tetrahydrocortisol and triamcinolone; - anti-bacterials and anti-infectives, such as aminoglycosides (e.g., tobramycin); quinolones (e.g., ciprofloxacin and ofioxacin); beta-lactams
(e.g., cephalosporins such as cefamandole); anti-fungals, such as natamycin; anti-virals, such as acyclovir and ganciclovir; - anti-cataract agents and anti-oxidants; anti-allergies; anti-metabolites, such as 5-fluorouracil (5-FU) and methotrexate; immunosuppressants, such as cyclosporin, FK-506 and leflunimide; growth factors such as EGF, FGF, PDGF; and - prodrugs of the drug classes listed above.
Combinations of ophthalmic agents may also be used in the compositions of the present invention. Further, in formulations without ophthalmic agents, the present invention may also serve to supplement tears in the prevention or treatment of dry eye.
The compositions of the present invention may additionally include other ophthalmically acceptable components: for example, buffers (e.g., phosphate, borate and citrate), chelating agents (e.g., EDTA), preservatives, (e.g., benzalkonium chloride, Polyquad® and Dymed® ) and tonicity agents (e.g., sodium chloride and mannitol). The compositions of the present invention may also include viscosity modifying agents such as: cellulosic ethers, such as, hydroxypropyl methyl cellulose (HPMC), hydroxyethyl cellulose (HEC), ethyl hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, and carboxymethyl cellulose; carbomers (Carbopol ); polyvinyl alcohol; polyvinyl pyrrolidone; alginates; carrageenans; and guar, karaya, agarose, locust bean, tragacanth and xanthan gums. The concentration of such viscosity modifiers will vary between about 0.1 to about 5 wt%, but such formulations will generally have a viscosity between about 10 and about 1000 centipoise.
The ophthalmic compositions containing TPGS may additionally contain polymers which will undergo sol-to-gel transition upon exposure to physical or chemical stimuli, such as changes in pH, ion concentration, and/or temperature.
The ophthalmic agents contained in the compositions of the present invention may optionally be encapsulated in microparticles. These loaded microparticles can be dispersed in aqueous vehicles containing TPGS to improve comfort. In addition, water-soluble or water-insoluble complexes of the ophthalmic agent can be incorporated in a vehicle containing TPGS. Example of water-soluble complexes include traditional complexes formed between the ophthalmic agent and caffeine, cyclodextrins, salicylates, benzoates. Examples of water insoluble complexes include ophthalmic agent - drug resin complexes.
The following examples are presented to illustrate further various aspects of the present invention, but are not intended to limit the scope of the invention in any respect.
EXAMPLE 1
The following formulations are representative of preferred compositions of the present invention.
FORMULATION (wt%)
INGREDIENTS A B C D E F G
Sodium Diclofenac 0.1 0.1 0.1 0.1 0.1 — 0.1
Dexamethasone — — — — — 0.1 —
Vitamin E TPGS (1000) 3.0 3.0 3.0 3.0 3.0 3.0 3.0
Tromethamine 0.23 0.23 0.23 1.2 1.2 — 0.23
Boric Acid 1.0 0.1 0.1 1.5 1.5 — . 1.0
Mannitol 4.0 — — 3.0 4.0 — 4.0
Benzalkonium Chloride 0.01 0.01 0.01 0.01 0.01 0.01 —
NaC1 — 0.7 0.7 — — — —
Disodium EDTA 0.1 0.1 0.1 0.1 0.1 — —
HPMC — 0.1 0.3 0.1 0.3 — —
Arginine — — — 0.5 — — —
HCI and/or NaOH pH to 7.4
Purified Water q.s. 100%
PreDaration:
Formulation D was prepared as follows, and Formulations A-C and E-G were prepared similarly.
A 10% (w/v) stock solution of vitamin E TPGS was prepared as follows.
Approximately 150 g of vitamin E TPGS was melted in a beaker by heating on a hot plate with stirring to ensure homogeneity. About 100 grams (g) of the molten TPGS was then added into 800 milliliters (mL) of near-boiling double distilled water. This mixture was stirred and allowed to cool to room temperature to ensure complete dissolution. Sufficient water was then added to the above solution to make a liter of stock solution.
Sodium diclofenac (0.3 g) was added to 90 mL of 10% TPGS stock solution. After complete dissolution of the diclofenac, the each of following ingredients were sequentially added to the solution with stirring so that each ingredient was completely dissolved before the next ingredient was added: 1.5 g of arginine, 9.0 g of mannitol, 4.5 g of boric acid, 3.6 g of tromethamine and 0.3 g of edetate sodium. To the above solution was added 6.0 mL of 0.5% solution of benzalkonium chloride, followed by the addition of 15 mL of 2% solution of HPMC. An additional 150 mL of water were added and the pH of the formulation adjusted to 7.4 with HCI and/or NaOH. To the resulting solution, enough water was added to bring the total solution volume to 300 mL. The osmolality of the final solution was about 300mOsm/kg.
EXAMPLE 2
The following formulation is another representative composition of the present invention, wherein a prostaglandin complexed with cyclodextrin is formulated in accordance with the teachings of the present invention.
INGREDIENT CONCENTRATION (wt%)
Prostaglandin 0.25
Hydroxypropyl-β-cyclodextrin 3.0 Tromethamine 1.2
Boric Acid 1.5
Mannitol 1.0
Benzalkonium Chloride 0.01
Disodium EDTA 0.1 Vitamin E TPGS (1000) 3.0
HCI/NaOH pH to 74.
Purified Water q.s. 100%
Preparation: Appropriate amounts of tromethamine, boric acid, mannitol, BAC and EDTA are added to 90 mL of a 10% stock solution of TPGS. In a separate container, 9 g of hydroxypropyl-β-cyclodextrin was dissolved in 150 mL of water. To this is added 0.75 g of a prostaglandin. The two solutions are then mixed together, the pH adjusted to 7.4, and water added to bring the volume to 300 mL. EXAMPLE 3
The following formulation is another representative composition of the present invention, wherein a prostaglandin bound to Duolite® (cholestyramine resins, available from Rohm & Haas, Philadelphia, Pennsylvania) is formulated in accordance with the teachings of the present invention.
INGREDIENT CONCENTRATION (wt%)
Prostaglandin 0.25 Duolite-® 0.25
Vitamin E TPGS 3.0
Tromethamine 1.2
Boric Acid 1.5
Mannitol 4.0 Benzalkonium Chloride 0.01
Disodium EDTA 0.1
HCI/NaOH pH to 7.4
Purified Water q.s. 100%
Preparation:
A prostaglandin (0.75 g) is dissolved in 200 mL of water. Finely divided Duolite (0.75 g) is added, and the solution allowed to equilibrate for 2 hours, during which time about 95% of the drug becomes bound to the resin. In a separate container, appropriate amounts of tromethamine, boric acid, BAC, edetate sodium and mannitol are added to 90 mL of the 10% TPGS stock solution. The two parts are then mixed and the pH adjusted to 7.4 with HCI and/or NaOH. Enough water is then added to the formulation to bring the final volume to 300 mL. The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.

Claims

What is claimed is:
1. An ophthalmic composition comprising: a therapeutically effective amount of one or more ophthalmic agents 5 selected from the group consisting of: anti-glaucoma agents, anti-hypertensives, non-steroidal anti-inflammatory agents, steroidal anti-inflammatory agents, anti- bacterials, anti-infectives, anti-fungals, anti-virals, anti-cataract agents, anti- oxidants, anti-allergics, anti-metabolites, immunosuppressants, growth factors, and prodrugs thereof; o an amount of a vitamin E tocopheryl derivative effective to reduce significantly the discomfort and irritation associated with topical ophthalmic administration of said ophthalmic agent; and an ophthalmically acceptable vehicle.
s 2. The composition of claim 1 , wherein the ophthalmic agent is a non-steroidal anti-inflammatory agent.
3. The composition of claim 2, wherein the non-steroidal anti-inflammatory agent comprises an aryl- or heteroaryl- alkanoic acid, or an ophthalmically o acceptable salt, ester or amide thereof.
4. The composition of claim 3, wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of: diclofenac, flurbiprofen, suprofen, ketorolac, indomethacin, ketoprofen and ophthalmically acceptable salts, esters or 5 amides thereof.
5. The composition of claim 4, wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of diclofenac and its ophthalmically acceptable salts, esters or amides. 0
6. The composition of claim 4, wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of suprofen and its ophthalmically acceptable salts, esters or amides.
7. The composition of claim 1 , wherein the vitamin E tocopheryl derivative is selected from one or more vitamin E polyoxyethylene glycol esters of a tocopheryl ester of succinic acid wherein the polyoxyethylene glycol moiety of the ester has a molecular weight in a range between about 600 and about 6000.
8. The composition of claim 7, wherein the polyoxyethylene glycol moiety of the ester has an average molecular weight of about 1000.
9. The composition of claim 1 , wherein the concentration of vitamin E tocopheryl derivative is less than about 30 percent by weight.
10. The composition of claim 9, wherein the concentration of vitamin E tocopheryl derivative is between about 0.1 and about 20 percent by weight.
11. The composition of claim 10, wherein the concentration of vitamin E tocopheryl derivative is between about 0.5 and about 10 percent by weight.
12. A method for treating or controlling ocular inflammation, comprising the topical ocular application of the composition of claim 2.
13. The method of claim 12, wherein the non-steroidal anti-inflammatory agent comprises an aryl- or heteroaryl- alkanoic acid, or an ophthalmically acceptable salt, ester or amide thereof.
14. The method of claim 13, wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of diclofenac and its ophthalmically acceptable salts, esters or amides.
15. A method for improving comfort and reducing irritation in ophthalmic compositions containing one or more ophthalmic agents which are irritating to the eye, comprising the step of adding to the ophthalmic composition an amount of a vitamin E tocopheryl derivative effective to reduce significantly the discomfort and irritation associated with topical ophthalmic administration of said ophthalmic agent.
16. The method of claim 15, wherein the vitamin E tocopheryl derivative is selected from one or more vitamin E polyoxyethylene glycol esters of a tocopheryl ester of succinic acid wherein the polyoxyethylene glycol moiety of the ester has a molecular weight in a range between about 600 and about 6000.
17. The method of claim 16, wherein the polyoxyethylene glycol moiety of the ester has an average molecular weight of about 1000.
18. The method of claim 15, wherein the concentration of vitamin E tocopheryl derivative is less than about 30 percent by weight.
19. The method of claim 18, wherein the concentration of vitamin E tocopheryl derivative is between about 0.1 and about 20 percent by weight.
20. The method of claim 19, wherein the concentration of vitamin E tocopheryl derivative is about 10 percent by weight.
PCT/US1995/005730 1994-05-06 1995-05-08 Use of vitamin e tocopheryl derivatives in ophthalmic compositions WO1995030420A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95919064A EP0708646A1 (en) 1994-05-06 1995-05-08 Use of vitamin e tocopheryl derivatives in ophthalmic compositions
AU24762/95A AU684950B2 (en) 1994-05-06 1995-05-08 Use of vitamin E tocopheryl derivatives in ophthalmic compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24005794A 1994-05-06 1994-05-06
US08/240,057 1994-05-06

Publications (1)

Publication Number Publication Date
WO1995030420A1 true WO1995030420A1 (en) 1995-11-16

Family

ID=22904935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/005730 WO1995030420A1 (en) 1994-05-06 1995-05-08 Use of vitamin e tocopheryl derivatives in ophthalmic compositions

Country Status (7)

Country Link
US (1) US5886030A (en)
EP (1) EP0708646A1 (en)
JP (1) JP2742333B2 (en)
CN (1) CN1129400A (en)
AU (1) AU684950B2 (en)
CA (1) CA2166722A1 (en)
WO (1) WO1995030420A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030022A1 (en) * 1995-03-29 1996-10-03 Alcon Laboratories, Inc. Topical ophthalmic formulations comprising an acidic drug, vitamin e tpgs, benzalkonium chloride and caffeine
WO1998006381A1 (en) * 1996-08-09 1998-02-19 Alcon Laboratories, Inc. Preservative systems for pharmaceutical compositions containing cyclodextrins
WO1998041208A1 (en) * 1997-03-17 1998-09-24 Novartis Ag Compositions and methods for reducing ocular hypertension
WO2000061189A3 (en) * 1999-04-02 2001-01-11 Ca Nat Research Council Water-soluble compositions of bioactive lipophilic compounds
US6193985B1 (en) 1994-05-16 2001-02-27 A/S Dumex (Dumex Ltd) Tocopherol compositions for delivery of biologically active agents
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6770675B2 (en) 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
US8524696B2 (en) 1999-04-02 2013-09-03 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US9192577B2 (en) 2002-11-29 2015-11-24 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid
KR20190098949A (en) * 2016-12-19 2019-08-23 라이온 가부시키가이샤 Ophthalmic composition and its manufacturing method

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166012A (en) * 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
US6552020B1 (en) * 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
UA75054C2 (en) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Substituted in position 6 indolinones, producing and use thereof as medicament
DE60111352T2 (en) * 2000-01-20 2006-05-04 Supratek Pharma, Inc., Montreal Podophyllotoxin COMPOSITIONS
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20030195179A1 (en) * 2000-08-25 2003-10-16 Shirou Sawa Aqueous suspension preparations
WO2002062344A1 (en) * 2001-02-02 2002-08-15 Cohen Ben Z Method of administering ophthalmic fluids
US7923469B2 (en) 2001-04-30 2011-04-12 Allergen, Inc. Compositions including vitamin-based surfactants and methods for using same
JP4255656B2 (en) * 2001-09-17 2009-04-15 株式会社メニコン Ophthalmic solution and contact lens solution
DE10161077A1 (en) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Highly concentrated stable meloxicam solutions for needleless injection
JP2005523262A (en) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming substances
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
WO2006121421A2 (en) * 2004-01-14 2006-11-16 Robert Ritch Methods and formulations for treating glaucoma
JP2007518804A (en) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド Composition for topical ophthalmic treatment preferably containing triamcinolone acetonide and hyaluronic acid
EP1568369A1 (en) * 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US20060073184A1 (en) * 2004-09-29 2006-04-06 Bausch & Lomb Inc. Viscoelastic composition, methods of use and packaging device with anti-oxidant
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
DK2564843T3 (en) 2005-06-01 2019-03-11 Bioelectron Tech Corp Redox-active therapeutics for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers
WO2007070463A2 (en) * 2005-12-12 2007-06-21 Riolan Technologies, Inc. Compositions, methods and kits for removing debris from an ocular area
JP5374162B2 (en) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド Modulation of redox-activated therapeutic side chain variants and energy biomarkers for the treatment of mitochondrial diseases and other conditions
WO2008002582A2 (en) * 2006-06-27 2008-01-03 Riolan Technologies, Inc. Ultraviolet absorbing ophthalmic compositions
AR066901A1 (en) * 2007-05-18 2009-09-23 Alcon Mfg Ltd PHODFOLIPID COMPOSITIONS FOR THE CLOSURE OF CONTACT LENSES AND PRESERVATION OF PHARMACEUTICAL COMPOSITIONS
EP2197461B1 (en) 2007-10-08 2018-02-21 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
GB0724772D0 (en) * 2007-12-19 2008-01-30 Ucl Business Plc Carrier
JP2011521957A (en) * 2008-05-28 2011-07-28 アルコン リサーチ， リミテッド Self-preserving emulsion
US8300252B2 (en) * 2008-06-18 2012-10-30 Livescribe, Inc. Managing objects with varying and repeated printed positioning information
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
US8314153B2 (en) 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
CN102238949A (en) * 2008-10-09 2011-11-09 拉姆斯科股份有限公司 Composition and method for treating dry eye syndrome
EP2367528A1 (en) * 2008-12-22 2011-09-28 Alcon Research, Ltd. Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
TW201038295A (en) * 2009-04-17 2010-11-01 Alcon Res Ltd Aqueous ophthalmic compositions containing anionic therapeutic agents
EA031126B1 (en) 2009-04-28 2018-11-30 Биоэлектрон Текнолоджи Корпорейшн Method of treating dominant optic atrophy with tocotrienol quinones
ES2537385T3 (en) * 2009-06-09 2015-06-08 Aurinia Pharmaceuticals Inc. Topical supply systems for ophthalmic use
CN102647971B (en) 2009-10-12 2016-03-16 贝林格尔.英格海姆维特梅迪卡有限公司 For comprising the container of the compositions of meloxicam
US20120295935A1 (en) * 2010-01-21 2012-11-22 Michael Frid Mixed aminal pharmaceutical compositions and uses thereof
SG183846A1 (en) 2010-03-03 2012-10-30 Boehringer Ingelheim Vetmed Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
IT1404931B1 (en) 2010-06-11 2013-12-09 Medivis S R L OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
CN108712903A (en) 2015-12-17 2018-10-26 生物电子技术有限公司 Fluoroalkyl, fluoroalkyl, phenoxy group, heteroaryloxy, alkoxy and amine 1,4- quinone derivatives for treating oxidation emergency obstacle
US11510931B2 (en) 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2019067919A1 (en) * 2017-09-28 2019-04-04 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
IT202000032687A1 (en) * 2020-12-29 2022-06-29 Nextera S A S Di Sacchetti Davide & C PEDIATRIC OPHTHALMIC COMPOSITION
IT202100006839A1 (en) 2021-03-22 2022-09-22 Omisan Farm S R L WATER-SOLUBLE OPHTHALMIC TOPICAL PREPARATION CONTAINING LUTEIN AND RELATED PRODUCTION METHOD

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60155111A (en) * 1983-10-20 1985-08-15 Hisamitsu Pharmaceut Co Inc Stable pharmaceutical for external use containing "ketoprofen(r)"
JPS6341421A (en) * 1986-08-07 1988-02-22 Sogo Yatsukou Kk Anticataract agent
EP0380367A1 (en) * 1989-01-27 1990-08-01 Stafford-Miller Ltd. Compositions and method for the treatment of disease
US5013751A (en) * 1989-01-10 1991-05-07 Alcon Laboratories, Inc. (+) Suprofen esters and amides as opthalmic anti-inflammatory agents
WO1993003720A2 (en) * 1991-08-16 1993-03-04 Trevithick John R Methods and compositions for treating sunburns
JPH05271076A (en) * 1992-03-26 1993-10-19 Taisho Pharmaceut Co Ltd Anti-inflammatory analgesic external preparation
EP0578077A2 (en) * 1992-07-10 1994-01-12 F. Hoffmann-La Roche Ag Compositions containing retinoic acids and tocopherol

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2680749A (en) * 1951-12-01 1954-06-08 Eastman Kodak Co Water-soluble tocopherol derivatives
US3102078A (en) * 1961-01-13 1963-08-27 Eastman Kodak Co Water-dispersible vitamin preparations
DE2530487A1 (en) * 1975-07-09 1977-01-27 Erfindergesellschaft Fresenius WATER SANITIZER AND METHOD FOR MANUFACTURING THEREOF
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4559343A (en) * 1982-09-07 1985-12-17 Alcon Laboratories, Inc. Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
JPS61184127A (en) * 1985-02-08 1986-08-16 Honda Motor Co Ltd Device for driving steered wheels of vehicle
FR2588189B1 (en) * 1985-10-03 1988-12-02 Merck Sharp & Dohme LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION
US5093126A (en) * 1987-09-26 1992-03-03 Alcon Laboratories, Inc. Glaucoma formulations comprising an anionic, polysulfonic acid polymer having mucomimetic properties and a polystyrene sulfonic polymer
MX9203804A (en) * 1987-10-19 1992-07-01 Liposome Co Inc PHARMACEUTICAL SYSTEMS BASED ON TOCOPHEROL.
DE3883246T2 (en) * 1987-10-19 1993-12-02 Liposome Co Inc MEDICINE SYSTEMS BASED ON TOCOPHEROL.
JPH01128921A (en) * 1987-11-12 1989-05-22 Taisho Pharmaceut Co Ltd Pharmaceutical for promoting absorption of vitamin a
US5198432A (en) * 1988-01-29 1993-03-30 Center For Innovative Technology Method of preventing chlorohydrocarbon toxicity using sterol derivatives
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
FR2685635B1 (en) * 1991-12-27 1995-06-30 Lvmh Rech COMPLEX SOLID PARTICLES COMPRISING A BIOLOGICALLY ACTIVE SOLID SUBSTANCE, THEIR METHOD OF PREPARATION AND TOPICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF BIOLOGICAL SURFACES.
JPH0468343A (en) * 1990-07-10 1992-03-04 Konica Corp Antistatic plastic film
JPH0537406A (en) * 1990-11-28 1993-02-12 Hitachi Ltd Tuner circuit
DK0495421T3 (en) * 1991-01-15 1996-12-09 Alcon Lab Inc Use of carrageenans in topical ophthalmic compositions
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
EP0724449A1 (en) * 1991-09-20 1996-08-07 Similasan Corporation Preservative for pharmaceutical products
NZ244862A (en) * 1991-10-23 1995-07-26 Block Drug Co Use of vitamin e in topical pharmaceuticals to enhance penetration of the active agent
JP2811036B2 (en) * 1992-05-26 1998-10-15 参天製薬株式会社 Vitamin E eye drops
CA2088927A1 (en) * 1993-02-11 1994-08-12 Donald Skeffington Preservative system for vitamin e aqueous solution
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
CA2221145A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60155111A (en) * 1983-10-20 1985-08-15 Hisamitsu Pharmaceut Co Inc Stable pharmaceutical for external use containing "ketoprofen(r)"
JPS6341421A (en) * 1986-08-07 1988-02-22 Sogo Yatsukou Kk Anticataract agent
US5013751A (en) * 1989-01-10 1991-05-07 Alcon Laboratories, Inc. (+) Suprofen esters and amides as opthalmic anti-inflammatory agents
EP0380367A1 (en) * 1989-01-27 1990-08-01 Stafford-Miller Ltd. Compositions and method for the treatment of disease
WO1993003720A2 (en) * 1991-08-16 1993-03-04 Trevithick John R Methods and compositions for treating sunburns
JPH05271076A (en) * 1992-03-26 1993-10-19 Taisho Pharmaceut Co Ltd Anti-inflammatory analgesic external preparation
EP0578077A2 (en) * 1992-07-10 1994-01-12 F. Hoffmann-La Roche Ag Compositions containing retinoic acids and tocopherol

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 8539, Derwent World Patents Index; AN 85-239345 *
DATABASE WPI Week 8813, Derwent World Patents Index; AN 88-089177 *
DATABASE WPI Week 9333, Derwent World Patents Index; AN 93-262882 *
DATABASE WPI Week 9346, Derwent World Patents Index; AN 93-365145 *
M.W. ADAMS: "d-Alpha tocopheryl polyethylene glycol 1000 succinate (Eastman vitamin E TPGS) as an emulsifier and bioenhancer for drugs and lipophilic compounds", CONGR. INT. TECHNOL. PHARM., 6TH, vol. 4, 1992, pages 254 - 262 *
POPOVICI I. ET AL: "FORMULATION ET ESSAIS IN VIVO DE COLLYRES HUILEUX D'INDOMETACINE", STP PHARMA SCI. (FRANCE), 1993, VOL. 3, NO. 3, PAGE(S) 266-270, *
R. CARINI ET AL.: "Comparative evaluation of the antioxidant activity of alpha-tocopherol, alpha-tocopherol polyethylene glycol 1000 succinate and alpha-tocopherol succinate in isolated hepatocytes and liver microsomal suspensions", BIOCHEMICAL PHARMACOLOGY, vol. 39, no. 10, 1990, pages 1597 - 1601 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6193985B1 (en) 1994-05-16 2001-02-27 A/S Dumex (Dumex Ltd) Tocopherol compositions for delivery of biologically active agents
WO1996030022A1 (en) * 1995-03-29 1996-10-03 Alcon Laboratories, Inc. Topical ophthalmic formulations comprising an acidic drug, vitamin e tpgs, benzalkonium chloride and caffeine
WO1998006381A1 (en) * 1996-08-09 1998-02-19 Alcon Laboratories, Inc. Preservative systems for pharmaceutical compositions containing cyclodextrins
US5985310A (en) * 1996-08-09 1999-11-16 Alcon Laboratories, Inc. Preservative systems for pharmaceutical compositions containing cyclodextrins
WO1998041208A1 (en) * 1997-03-17 1998-09-24 Novartis Ag Compositions and methods for reducing ocular hypertension
CZ299833B6 (en) * 1997-03-17 2008-12-10 Novartis Ag Ophthalmic composition for reducing ocular hypertension containing prostaglandin active substance
US6770675B2 (en) 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
AU775059B2 (en) * 1999-04-02 2004-07-15 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6191172B1 (en) 1999-04-02 2001-02-20 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
WO2000061189A3 (en) * 1999-04-02 2001-01-11 Ca Nat Research Council Water-soluble compositions of bioactive lipophilic compounds
US7645816B2 (en) 1999-04-02 2010-01-12 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US8524696B2 (en) 1999-04-02 2013-09-03 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US9192577B2 (en) 2002-11-29 2015-11-24 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid
KR20190098949A (en) * 2016-12-19 2019-08-23 라이온 가부시키가이샤 Ophthalmic composition and its manufacturing method
KR102453524B1 (en) 2016-12-19 2022-10-12 라이온 가부시키가이샤 Ophthalmic composition and manufacturing method thereof

Also Published As

Publication number Publication date
JPH08508049A (en) 1996-08-27
CA2166722A1 (en) 1995-11-16
MX9600140A (en) 1998-11-29
AU684950B2 (en) 1998-01-08
AU2476295A (en) 1995-11-29
JP2742333B2 (en) 1998-04-22
EP0708646A1 (en) 1996-05-01
CN1129400A (en) 1996-08-21
US5886030A (en) 1999-03-23

Similar Documents

Publication Publication Date Title
US5886030A (en) Use of vitamin E tocopheryl derivatives in ophthalmic compositions
EP0739197B1 (en) Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
JP5161950B2 (en) Ophthalmic composition comprising a synergistic combination of three polymers
AU2010200297B2 (en) Ophthalmic compositions containing a synergistic combination of two polymers
US7914803B2 (en) Ophthalmic compositions containing a synergistic combination of three polymers
JP2002509101A (en) Autoclavable pharmaceutical composition containing a chelating agent
EP1782816A1 (en) Water-based medicinal composition containing azithromycin and method of preparing the same
US4623664A (en) Oil suspended phenylephrine
MXPA96000140A (en) Use of tocyferyl derivatives of vitamin e in oftalmi compositions
TWI253345B (en) Ophthalmic composition for the treatment of glaucoma, ocular hypertension, ocular ischemia and related disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95190533.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP MX

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1995919064

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2166722

Country of ref document: CA

Ref document number: PA/a/1996/000140

Country of ref document: MX

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1995919064

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995919064

Country of ref document: EP